+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System Therapeutics Market - Global Forecast 2026-2032- Product Image
Central Nervous System Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Central Nervous System Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5665844
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The central nervous system therapeutics market is characterized by rapid innovation and increasing complexity, presenting decisive opportunities and challenges for executive leaders across the pharmaceutical and healthcare ecosystem. Stakeholders are navigating evolving therapies, shifting regulatory landscapes, and realignment in global markets.

Market Snapshot: Central Nervous System Therapeutics Market

In 2025, the global central nervous system therapeutics market was valued at USD 152.33 billion, rising to USD 163.52 billion in 2026 and projected to see sustained expansion at a CAGR of 7.54%, reaching USD 253.54 billion by 2032. The sector’s trajectory is shaped by breakthrough scientific advances and demographic forces, reinforcing its role as a priority business segment for pharmaceutical manufacturers, suppliers, and healthcare providers.

Scope & Segmentation

  • Drug Classes: Includes antidepressants, antipsychotics, anticonvulsants, anxiolytics, anesthetics, pain relievers, and CNS stimulants, ranging from established generics to advanced biologics and gene therapies.
  • Disease Indications: Covers neurodegenerative illnesses such as Alzheimer’s, Parkinson’s, Huntington’s, and multiple sclerosis, major psychiatric conditions including depression, anxiety, schizophrenia, bipolar disorder, and acute conditions (e.g., stroke, brain injury, spinal cord injury).
  • Route of Administration: Oral and injectable products form the market backbone, with increasing attention to transdermal and alternative delivery platforms enhancing adherence and outcomes.
  • Mechanisms of Action: Encompasses disease-modifying agents, symptom control therapies, gene and peptide-based treatments, and monoclonal antibodies targeting complex pathophysiology.
  • End Users: Products are delivered in hospitals, clinics, and home care settings, with distribution tailored to severity, monitoring requirements, and patient preferences.
  • Distribution Channels: Offline and online pharmacies address evolving patterns in access, privacy, and convenience, intersecting with digital engagement and real-world adherence solutions.
  • Regions: Study spans the Americas, EMEA, and Asia-Pacific, detailing regulatory, reimbursement, and care-model differences that influence market entry and expansion strategies.
  • Technologies: Salient focus on digital health integration, precision approaches using biomarkers and pharmacogenomics, advanced imaging, and AI-facilitated discovery platforms.

Key Takeaways for Executive Decision-Makers

  • Growth is driven by a shift from symptom-centric drugs to precision and disease-modifying therapies, leveraging advances in molecular biology and data-enabled medicine.
  • Formulation innovation, such as long-acting injectables and transdermal systems, is elevating patient adherence and broadening deployment beyond hospital settings.
  • Integration of digital tools and real-world data is streamlining clinical development, enabling finer segmentation and more adaptive trial design across neurological and psychiatric indications.
  • Competitive differentiation in mature segments increasingly relies on adherence support, safety/tolerability profiles, and digital engagement rather than primary pharmacological novelty.
  • Emerging regional and regulatory requirements are prompting companies to recalibrate market access, with payer scrutiny and health technology assessment shaping portfolio priorities worldwide.
  • Effective partnerships—spanning academia, digital health, manufacturing, and diagnostics—are central to accelerating time-to-market and optimizing commercialization, particularly for advanced CNS therapeutics.

Tariff Impact: U.S. Trade Policy and CNS Therapeutics

Anticipated United States tariffs in 2025 are poised to affect central nervous system therapeutic supply chains, cost structures, and pricing decisions. While broad in application, these trade measures may indirectly elevate production costs, particularly for generic drug categories and for innovators relying on global sourcing for specialized components. Manufacturers are responding by stress-testing supply chains, exploring new supplier networks, and evaluating regional manufacturing realignment to mitigate disruption and ensure continuity across the value chain.

Methodology & Data Sources

The report draws on primary research with senior industry stakeholders, extensive secondary analysis, regulatory filings, and real-world healthcare utilization data. Advanced modeling supports accurate forecasting, while qualitative insights from executives, clinicians, and supply chain leaders provide essential market context.

Why This Report Matters

  • Enables senior decision-makers to anticipate structural shifts impacting CNS therapeutics investment, regulatory planning, and commercial execution.
  • Provides actionable segmentation and regional intelligence to inform portfolio development, market entry, and go-to-market strategies.
  • Equips commercial, R&D, and policy teams with evidence to benchmark innovation, resilience, and competitive advantage in a dynamic market landscape.

Conclusion

With innovation and realignment accelerating across central nervous system therapeutics, senior leaders need integrated insights to inform strategic planning, investment, and market positioning. This report delivers an evidence-based foundation to unlock new opportunities and sustain growth in the evolving CNS landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Central Nervous System Therapeutics Market, by Drug Class
8.1. Antidepressants
8.2. Antipsychotics
8.3. Anticonvulsants
8.4. Anxiolytics
8.5. Anesthetics
8.6. Pain Relievers
8.7. CNS Stimulants
9. Central Nervous System Therapeutics Market, by Disease Indication
9.1. Neurodegenerative Disorders
9.1.1. Alzheimer's Disease
9.1.2. Parkinson's Disease
9.1.3. Huntington's Disease
9.1.4. Multiple Sclerosis
9.2. Psychiatric Disorders
9.2.1. Major Depressive Disorder
9.2.2. Anxiety Disorders
9.2.3. Schizophrenia
9.2.4. Bipolar Disorder
9.3. Neurovascular Diseases
9.3.1. Stroke
9.3.2. Cerebral Aneurysm
9.4. CNS Trauma
9.4.1. Traumatic Brain Injury (TBI)
9.4.2. Spinal Cord Injury
10. Central Nervous System Therapeutics Market, by Route Of Administration
10.1. Injectable
10.2. Oral
10.3. Transdermal
11. Central Nervous System Therapeutics Market, by Mechanism Of Action
11.1. Gene Therapy
11.2. Monoclonal Antibodies
11.3. Peptides
11.4. Small Molecules
12. Central Nervous System Therapeutics Market, by End User
12.1. Clinics
12.2. Home Care
12.3. Hospitals
13. Central Nervous System Therapeutics Market, by Distribution Channel
13.1. Offline Pharmacies
13.2. Online Pharmacies
14. Central Nervous System Therapeutics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Central Nervous System Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Central Nervous System Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Central Nervous System Therapeutics Market
18. China Central Nervous System Therapeutics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. AC Immune SA
19.7. Acadia Pharmaceuticals, Inc.
19.8. Alkermes plc
19.9. Amgen Inc.
19.10. Anavex Life Sciences Corp.
19.11. Biogen Inc.
19.12. Bristol-Myers Squibb Company
19.13. Eli Lilly and Company
19.14. F. Hoffmann-La Roche Ltd.
19.15. GSK plc
19.16. H. Lundbeck A/S
19.17. Ipsen S.A.
19.18. Jazz Pharmaceuticals plc
19.19. Johnson & Johnson
19.20. Merck & Co., Inc.
19.21. Neumora Therapeutics, Inc.
19.22. Neurocrine Biosciences, Inc.
19.23. Neurona Therapeutics Inc.
19.24. Novartis AG
19.25. Otsuka Pharmaceutical Co., Ltd.
19.26. Pfizer Inc.
19.27. PTC Therapeutics, Inc.
19.28. Sanofi S.A.
19.29. Sumitomo Pharma Co., Ltd.
19.30. Supernus Pharmaceuticals, Inc.
19.31. Takeda Pharmaceutical Company Limited
19.32. Teva Pharmaceutical Industries Ltd.
19.33. UCB S.A.
19.34. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIOLYTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN RELIEVERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN RELIEVERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN RELIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CEREBRAL ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CEREBRAL ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CEREBRAL ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY (TBI), BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY (TBI), BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY (TBI), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 165. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 166. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 167. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 168. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 169. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 171. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 186. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 187. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 188. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 189. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 190. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 191. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 193. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 210. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 211. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 213. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 214. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 216. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. ASEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 220. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 221. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 222. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 223. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 224. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 225. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 227. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. GCC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 243. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 244. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 245. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 246. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 247. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 249. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. BRICS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 252. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 254. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 255. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 256. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 257. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 258. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 260. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. G7 CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 263. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 264. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 265. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 266. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 267. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 268. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS TRAUMA, 2018-2032 (USD MILLION)
TABLE 269. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 271. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. NATO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 273. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES CENTRAL NERVOUS

Companies Mentioned

The key companies profiled in this Central Nervous System Therapeutics market report include:
  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Anavex Life Sciences Corp.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • H. Lundbeck A/S
  • Ipsen S.A.
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neumora Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.
  • Neurona Therapeutics Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 163.52 Billion
Forecasted Market Value ( USD ) by 2032 $ 253.54 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Central Nervous System Drugs Market - Global Forecast 2026-2032 - Product Image

Central Nervous System Drugs Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Central Nervous System Therapeutics Market - Global Strategic Business Report - Product Image

Central Nervous System Therapeutics Market - Global Strategic Business Report

  • Report
  • 395 Pages
  • Global
From
Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2025-2033 - Product Image

Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2025-2033

  • Report
  • 136 Pages
  • Global
From
Central Nervous System Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Central Nervous System Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Central Nervous System Therapeutics Market Report 2025 - Product Image

Central Nervous System Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.